Investment Gems

What The Chart Is Saying: At The Highs, On Financing Fuel

The tape and the filings tell the same story, and it isn’t a fresh breakout.

Source: TradingView

Over the past twelve months LGND has run from a 52-week low of $112 to a 52-week high of $306, close to a triple, and at $304 it sits at the very top of that range, essentially at all-time highs. That is the opposite of the setup I usually want to buy. A stock breaking out of a long base on the first recognition of a fundamental change offers asymmetry; a stock that has already tripled and is making new highs on a financing event offers the inverse.

The most recent leg is the tell. The stock jumped roughly 16% in the final week of June, but the proximate cause was the pricing of $625M of convertible notes due 2031 (struck around a $334 conversion price, a 27.5% premium to the $262 reference), capital earmarked for the XOMA acquisition. Financing-driven spikes are not the same as fundamental breakouts: they pull the price forward, they don’t reset the base.

So the chart says what the numbers say. There is no technical edge at $304: you are buying new highs, on financing fuel, at a multiple that already assumes the bull re-rating. Usually, I don’t advise it, but sometimes it can work.

Business Overview: A Royalty Aggregator That Actually Works

Ligand is not a drug company in the usual sense. It doesn’t run salesforces or own factories. It finances and licenses other people’s high-value medicines and collects royalties, a Royalty-Pharma-style model in small-cap form.

The transformation dates to 2022. Management (CEO Todd Davis) divested two infrastructure-heavy platform businesses, cut from 200 employees to 40, and dropped operating expenses from the $90M range to $40M. What replaced the platforms was an 18-person investment team running three plays: royalty monetizations (buying existing license streams), project finance (funding late-stage development for a royalty), and special situations (rescuing good assets stuck in distressed structures, sometimes operating or re-partnering them). The result: commercial assets went from 7 to 15, the team closed 18 deals in three years, and the model now throws off enough cash ($300M of 2027 operating cash flow expected) to nearly self-fund a $150–250M annual deal pace.

The economics are why it works. Royalty income carries very high incremental margins, the cash flows are recurring and long-dated, and Ligand is passive on the hard part, its partners (Travere, Merck, Verona, Sanofi, Amgen, Jazz, Palvella and others) do the commercializing. Q1 showed the leverage: royalty revenue up 56% to $43M, total revenue up 14% to $52M, adjusted EPS up 23% to $1.63, and operating cash flow swinging to +$49M. (The GAAP net loss of $0.67/share is noise, a $49M non-cash mark-to-market hit on equity stakes like Pelthos and Viking; I’ll come back to why that “noise” is also a risk.)

The Bull Case: The Assets That Can Actually Move The Needle

A 56%-royalty-growth quarter is the headline; the assets behind it are the thesis. The bull case rests on a diversified book, 12 major royalty drivers today, soon 120+ with XOMA, plus genuine pipeline optionality. Here are the pieces with the weight to matter.

Filspari (the largest royalty, now with two diseases). Filspari (sparsentan, partnered with Travere) is Ligand’s single biggest royalty, and in April it won full FDA approval in FSGS, a second rare kidney disease, with a broad label covering primary, secondary and genetic forms, making it the first and only approved FSGS therapy. Travere already fields 100+ reps with heavy overlap between IgAN and FSGS prescribers and established payer coverage, so the launch should ramp fast (first patients were dosed within a week of approval). Travere guides to a $3B peak combined opportunity to roughly $270M in annual royalty to Ligand if achieved. This one asset can carry years of growth.

The XOMA acquisition (scale in a single step). Announced in April and closing in Q3, the $739M XOMA Royalty deal adds 120+ assets, seven marketed products (including VABYSMO, OJEMDA and Miplyffa), 14 late-stage clinical programs and 100+ early-stage shots, some with royalty rights running past 2040. Management pegs synergies “approaching 100%” because passive contractual royalties fold straight into existing infrastructure, and the deal transfers Section 174 R&D tax credits usable immediately, lifting combined 2027 operating cash flow toward $300M. It’s accretive day one (+$0.50 EPS in 2026, +$1.50 in 2027). There’s even a free option attached: a CVR on XOMA’s litigation against Janssen where Ligand keeps 25% of any proceeds with no obligation to fund the case.

Palvella’s QTORIN rapamycin (the optionality). Palvella’s Phase III SELVA trial in microcystic lymphatic malformations didn’t just hit, it posted a +2.13-point improvement against a +1.0 “decisive win” bar and a +1.5 “upside” case. NDA submission is slated for 2H 2026, with a second indication (CVM) behind it. Across both, 100,000+ patients at $100–200k/year of pricing frame a $1–3B US sales opportunity to $100–300M peak annual royalty to Ligand. None of this is in the current numbers.

The Merck and specialty book (the ballast). Ohtuvayre (COPD, via Verona/Merck) is growing strongly; Merck’s Capvaxive and Vaxneuvance pneumococcal vaccines, Amgen’s Kyprolis, Jazz’s Rylaze, the Pelthos-spun Zelsuvmi (13% royalty) and Qarziba (neuroblastoma, from the 2024 Apeiron deal) round out a genuinely diversified stream, no single product is a point of failure for the whole.

The compounding flywheel (why a premium multiple is even on the table). The reason this can get a growth multiple rather than a royalty-trust multiple: management says >20% annual growth is embedded for five years with no new deals, yet the $1B of dry powder and near-self-funding cash generation mean new deals keep coming on top. Tax-efficient cash funds more royalties, which generate more cash. That flywheel, capital-light, IP-owning, compounding, is structurally the same engine that earns ARM Holdings a premium most companies never see. Whether Ligand gets paid for it is the entire valuation debate.

The Valuation

Here is the unusual thing about Ligand at $304: the analysts barely disagree about the earnings. The 2027 adjusted-EPS estimates run from a $6.4 low to a $10.09 high, clustered around $8.2. When the earnings range is that tight, the stock price is not really a bet on the business, it’s a bet on what multiple the market is willing to pay for that business. And on multiple, the disagreement is enormous.

That’s because Ligand sits between two very real, very public peers that price the exact same business model completely differently:

• At the floor, Royalty Pharma (RPRX) — the large, established royalty aggregator, the closest thing to a pure comp. The market treats royalty aggregation as a low-growth, spread-lending-like business and pays RPRX about 11x forward earnings. That is the “it’s just a royalty trust” multiple.
• At the ceiling, ARM Holdings (ARM) — not a biotech, but the purest large-cap example of Ligand’s type: a capital-light company that owns IP, lets others do the manufacturing and selling, and compounds royalties at high incremental margins. The market adores that model and pays ARM roughly 150x forward earnings (and ~70x sales). Ligand is, in spirit, a biotech version of the same engine.

Ligand will likely never command ARM’s AI-narrative multiple, I’m not arguing it should. But these two names define the field of play, and right now Ligand trades at ~27x forward adjusted EPS: already far above the RPRX “trust” floor, already being paid as a compounder.

I project adjusted EPS to year-end 2027, take the analyst high and low estimates as the bull and bear earnings, and anchor the exit multiples to those two peers:

Scenario	FY2027E Adj. EPS	Exit Multiple (peer-anchored)	Implied Price	Annual Return @ $304
Bull	$10.09 (analyst high — Filspari FSGS ramps, XOMA milestones flow, Palvella optionality starts to price in)	50x — market keeps re-rating toward the compounder; still only a fraction of ARM’s ~150x	~$504.5	+29%
Bear	$10.00 (analyst low — XOMA integration lumpy, a marquee royalty stalls)	11x — de-rates to Royalty Pharma, “just another royalty trust”	~$70.4	−51.8%

A few things stand out, and they’re the whole argument:

The asymmetry is not in the earnings, it’s in the multiple. Bull-to-bear EPS only spans $10.00 to $12.58. The price outcomes span $110 to $500. That gap between the trust multiple (11x) and the compounder multiple (~27x today, ~50x in the bull) is doing all of the work. Buying here is, functionally, a leveraged bet that the market keeps believing the compounder story, with no cushion if it stops.

I am deliberately not timid on the bull. Fifty times forward earnings on a >20% grower is a rich multiple, and I’m using it anyway, because that is the honest expression of what this model can earn if the flywheel keeps turning, and it is still barely a third of what the market pays ARM. If Ligand captured even half of ARM’s multiple (~75x), the bull is closer to +148%. The ceiling here is genuinely high. The problem is purely the entry.

Risks

The multiple is the entire bet, and you’re paying the high end of it. At 27x forward earnings the compounder re-rating is already priced; the ~16-turn gap down to Royalty Pharma’s ~11x is the bear. Any stumble flips the market’s frame from “ARM-like compounder” to “just a royalty trust,” and that re-rate is a −51% move on roughly unchanged earnings.

Ligand is passive on execution. It collects royalties; partners (Travere, Merck, Verona, Sanofi, Palvella) control commercialization, pricing and the competitive response. Filspari is now the single largest royalty just as IgAN gets more crowded and the FSGS launch is still unproven.

XOMA integration and funding. A $739M deal carries milestone and revenue lumpiness, and the converts used to fund it ($1.07B face across the 2030 and 2031 notes) add leverage and dilution risk if the stock pushes past ~$334.

GAAP volatility is also real risk. The equity stakes (Viking, Pelthos and others) that create “adjusted-out” mark-to-market swings can also genuinely impair, the adjusted figures hide that portfolio exposure.

Pipeline binaries. Palvella, Orchestra BioMed, LeonaBio and XOMA’s Mirum readouts and milestones are not guaranteed; royalty assets can and do fail in trials, which is exactly what would push the market toward the bear multiple.

Conclusion

Ligand is the rare royalty story where the model demonstrably works: a disciplined 40-person team has compounded adjusted EPS from $2.44 to ~$9, built a diversified 12-driver royalty book led by a newly two-disease Filspari, layered on the transformational XOMA acquisition, and carries enough dry powder and cash generation to keep the flywheel turning with >20% embedded growth and Palvella-sized optionality on top. Structurally, it is a biotech cousin of the capital-light IP-royalty compounders the market pays up for. The business deserves a Buy.

The stock, at $304, does not, yet. The analysts agree on the earnings; the only open question is the multiple, and the market has already moved Ligand most of the way from the Royalty-Pharma “trust” multiple toward the compounder multiple it would need the bull case to justify. That leaves a flat base case, a genuinely large +29% bull if the re-rating runs to 50x (still a fraction of ARM), and a −51.8% bear if it ever snaps back to its only true peer near 11x. I rate LGND a Hold, and I’d flip to Buy on either of two triggers: a pullback into the mid-$200s ($215–240), where the same bull math survives but the downside is cushioned, or a beat-and-raise, most likely the December 2026 Investor Day five-year update, that pushes consensus toward the high estimate and lets the company grow into the compounder multiple instead of merely being granted it. This is a franchise I want to own, but at this price, I am not adding more.

---

Disclosure: Long LGND.

This text expresses the views of the author as of the date indicated, and such views are subject to change without notice. The author has no duty or obligation to update the information contained herein. Further, wherever there is the potential for profit, there is also the possibility of loss. Additionally, the present article is being made available for educational purposes only and should not be used for any other purpose. The information contained herein does not constitute and should not be construed as an offering of advisory services or an offer to sell or solicitation to buy any securities or related financial instruments in any jurisdiction. Some information and data contained herein concerning economic trends and performance is based on or derived from information provided by independent third-party sources. The author trusts that the sources from which such information has been obtained are reliable; however, it cannot guarantee the accuracy of such information and has not independently verified the accuracy or completeness of such information or the assumptions on which such information is based.